RIC
- Generic Name
- RIC
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Phase 1
Recruiting
- Conditions
- HIVHematologic Malignancies
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 265
- Registration Number
- NCT05470491
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Peripheral T-cell LymphomasLymphoproliferative DisordersImmune System Diseases
- Interventions
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 330
- Registration Number
- NCT03922724
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸National Marrow Donor Program, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath